Fig. 1.

Generic monoclonal antibody-derived therapeutic structures as adapted from IMGT (Lefranc et al. 2009; World Health O 2006). Fc constant region which contributes to effector function, immune response and increased half-life, Fv variable region that contains complementarity determining regions (CDRs) facilitating antigen binding, Fab antigen binding fragment which lacks Fc region, scFv single chain fragment variable, FP Fc fusion proteins that contain Fc region for effector functionality (e.g. Abatacept), CP composite protein that contains Fc region for increasing half-life and not for effector functionality (e.g. Strensiq™) (World Health 2006)